September 20, 2016
Cambridge, MA

The First Therapy for Duchenne Muscular Dystrophy

Solid Biosciences congratulates Sarepta on the U.S. approval of EXONDYS 51™ (eteplirsen), the first therapy for Duchenne muscular dystrophy. It would not have been possible without the tireless work and commitment of the team at Sarepta, the patient community, the FDA and all those driven to make an approved therapy a reality.

We at Solid hope this event marks the first of many approvals for future therapies that will benefit all patients with this devastating disease. Our mission is to discover and develop treatments that address the full spectrum of Duchenne muscular dystrophy – from its underlying cause to the secondary disorders that result from the disease.

Related news


Grants from the charities Duchenne Now, Save Our Sons and Fight DMD will support important work in furthering Solid’s gene therapy and disease modifying therapy programs.


The biologic candidate LTBP4 has the potential to promote muscle health and reduce fibrosis in patients with Duchenne muscular dystrophy.


Carl Morris, Solid Biosciences’ vice president of Research and Development, speaks about being a “Game Changer in Rare Disease.”


More information about Solid?

Please subscribe to receive our latest news